– Review of Scientific Advice sought by the industry related to pre-clinical safety testing – Joint revision and development of multidisciplinary guidelines and points to consider documents with other Working Parties: • Note for guidance on gene transfer medicinal products (with Biotechnology Working Party) • Points to consider document on xenogeneic cell therapy (with Biotechnology Working Party) • Note for guidance on specification limits for residues of heavy metal catalysts in active substances and in medicinal products (with Joint Quality Working Party) • Revision of Note for guidance on radiopharmaceuticals (with Joint Quality Working Party)